Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “VESTIBULAR FUNCTION TESTS”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 901 records · Page 50Linked to original sources
PubMed1981

Tobramycin therapy of serious infections. Pharmacological aspects and side effects.

Plasma concentrations and side effects were followed in 52 adults treated with tobramycin for 4-39 days (mean 12.2 days). In order to obtain 1-h peak levels above the recommended 4 microgram/ml in patients with normal renal function, loading doses of 160 mg followed by 100-120 mg every 8 h were usually necessary. Both the leading dose and the mean daily dose of 304 mg were higher than usually recommended. Great individual variations in doses required were found and nomograms were of little value. Reduced maintenance doses were given to patients with impaired renal function. Adequate treatment required plasma level determinations 2-3 times a week. The high dose of tobramycin regimen used in this study implied that 30% of the trough levels exceeded 2 microgram/ml. The frequency of clinically significant side effects were, however, low and the treatment was only interrupted once because of a decrease in renal function. Temporary reduction in renal function probably related to tobramycin was found in 6 patients, and 5 patients got temporary disturbances of vestibular function. One patient experienced a temporary hearing loss and 2 patients a permanent hearing loss, which might have been caused by simultaneous treatment with furosemide and tobramycin.

Adult↗
PubMed2000

Long-term vestibulo-ocular reflex changes in patients with vestibular ablation.

Long-term changes in the parameters of the vestibulo-ocular reflex (VOR) were evaluated using recently developed multilevel statistical modelling techniques in a group of patients who had undergone ablative inner ear procedures. Data from 84 patients were available for study. The most dramatic recovery in the VOR occurred during the first 60 postoperative days, however, slow changes continued, levelling off at about 120 days. While frequency was a highly significant predictor of outcomes in all parameters, age showed significant predictive value only to phase measures (p = 0.006) and gender had no effect. Sum gain at the lowest frequency tested remained below the 5th percentile and at the higher frequencies remained below the 50th percentile for normal subjects. Phase decreased exponentially, but remained above the 95th percentile for normal subjects, except at the highest frequency where it remained above the 50th percentile. DC bias decreased exponentially, dropping to the 50th percentile by day 146. Asymmetry stayed between the 50th and 95th percentile, except at the highest frequency, where it was at the 50th percentile by day 125.

Female↗
PubMed2006

Vestibular evoked myogenic potentials.

PURPOSE OF REVIEW: Vestibular evoked myogenic potential testing is the only clinically feasible way to measure function of the saccule. Interest in this test has exploded in recent years because of its potential utility in diagnosing third-window disorders and in diagnosing and monitoring Ménière's disease. RECENT FINDINGS: Recent literature on vestibular evoked myogenic potential covers a wide range of topics. Review articles, method articles and many case reports and uncontrolled case series are seeking new applications for vestibular evoked myogenic potential in diagnosis and monitoring of neurotologic disease, and in shedding light on inner ear diseases by mapping anatomic sites of involvement. The most informative work is still in the areas of superior semicircular canal dehiscence and in Ménière's disease. Also, many aspects of vestibular evoked myogenic potential and its use have not yet been adequately studied or described. SUMMARY: Vestibular evoked myogenic potential is a new test of saccular and inferior vestibular nerve integrity. It holds great promise for diagnosing and monitoring Ménière's disease and some other neurotologic disorders. It is still an evolving field, however. The methods, equipment, and applications for vestibular evoked myogenic potential testing are not yet standardized. It is not yet time for this test to be widely applied, but that time is not far off.

Acoustic Stimulation↗
PubMed1987

A study of potential vestibulotoxic effects of once daily versus thrice daily administration of tobramycin.

Tobramycin 5.1 mg/kg/day was administered for 9 days to 20 healthy human volunteers to determine the potential vestibulotoxicity of once daily versus thrice daily treatment regimens. Vestibular function was tested carefully before, during, and following drug administration, using a battery of postural and caloric tests. Although subjects receiving the once daily regimen performed better on the postural tests, we feel this does not necessarily indicate an adverse effect in either group. The caloric test was the primary measure of vestibular function in this experiment, and this test appeared to demonstrate a slight adverse effect during drug administration of equal magnitude in both treatment groups. The results of this experiment indicate that there is no significant difference in the risk of adverse vestibular effects between once daily and thrice daily tobramycin administration.

Adult↗
PubMed2004

Benign paroxysmal positional nystagmus in hospitalized subjects receiving ototoxic medications.

OBJECTIVE: To investigate the occurrence of benign paroxysmal positional nystagmus in subjects undergoing treatment with potentially ototoxic medications. STUDY DESIGN: Prospective and retrospective record reviews. SETTING: Tertiary referral neurotology clinic; clinical research and technology center. SUBJECTS: Ninety-nine hospitalized subjects undergoing treatment of infectious disease or carcinoma with potentially ototoxic medications. INTERVENTIONS: Records review, tests of vestibular function. MAIN OUTCOME MEASURE: Results of Hallpike positional tests for benign paroxysmal positional nystagmus (electro-oculography). RESULTS: Forty-one (41%) of 99 subjects were female and 58 (59%) were male. Age range was 15 to 73 years (mean, 47 years). Forty-nine (50%) of 99 subjects had an unequivocally positive Hallpike test for benign paroxysmal positional nystagmus in one or both ears. The occurrence of benign paroxysmal positional nystagmus in the Hallpike-positive population was distributed equally across age decades. Of the 49 subjects with benign paroxysmal positional nystagmus, 22 (44%) were female and 27 (56%) were male. CONCLUSIONS: Benign paroxysmal positional nystagmus is the most common cause of vertigo in the general population, including subjects receiving ototoxic drugs. Complaints of vertigo in subjects receiving ototoxic drugs therefore may or may not indicate onset of ototoxicity. Occurrence of benign paroxysmal positional nystagmus in subjects receiving ototoxic drugs was independent of gender or age. The high occurrence rate of benign paroxysmal positional nystagmus in subjects receiving potentially ototoxic medications is consistent with the observation that benign paroxysmal positional nystagmus occurs in combination with many pathologic conditions. Benign paroxysmal positional nystagmus presenting in subjects receiving ototoxic drugs may complicate the clinical identification of ototoxicity and obfuscate clinical decision-making processes.

Adolescent↗